Stock MVIR B MEDIVIR AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Medivir AB

Equities

MVIR B

SE0020181014

Biotechnology & Medical Research

Real-time Estimate Cboe Europe
Other stock markets
 08:55:00 28/06/2024 pm IST 		5-day change 1st Jan Change
2.995 SEK -3.39% Intraday chart for Medivir AB 0.00% +3.51%
27/06 Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide + Lenvima® in Advanced Hepatocellular Carcinoma CI
20/06 Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 20-JUN-2024. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 301.2 201.5 624.1 551.7 159.1 347.7 - -
Enterprise Value (EV) 1 210.5 131.5 402.9 434.3 -10.48 172.5 80.72 282.7
P/E ratio -2.44 x -4.74 x -9.33 x -6.23 x -1.93 x -3.88 x -2.44 x -2.12 x
Yield - - - - - - - -
Capitalization / Revenue 41.8 x 5.11 x 17.5 x 89 x 17.7 x 11.7 x 6.68 x 34.1 x
EV / Revenue 29.2 x 3.34 x 11.3 x 70 x -1.16 x 5.8 x 1.55 x 27.7 x
EV / EBITDA -1.77 x -3.42 x -6.77 x -5.12 x 0.12 x -2.82 x -2.71 x -2.19 x
EV / FCF -1.41 x -2.07 x -8.27 x -4.25 x 0.17 x -7.19 x -0.47 x -1.39 x
FCF Yield -71.1% -48.3% -12.1% -23.5% 572% -13.9% -211% -72.2%
Price to Book 1.63 x 1.42 x 2.22 x 2.86 x 0.79 x 1.05 x 1.06 x 2.79 x
Nbr of stocks (in thousands) 24,288 24,276 55,724 55,724 55,830 1,12,168 - -
Reference price 2 12.40 8.300 11.20 9.900 2.850 3.100 3.100 3.100
Announcement Date 13/02/20 26/02/21 15/02/22 15/02/23 15/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7.2 39.4 35.7 6.2 9 29.72 52.05 10.2
EBITDA 1 -118.9 -38.5 -59.5 -84.8 -88.7 -61.2 -29.8 -129
EBIT 1 -126 -42.9 -62.1 -87.4 -91.4 -97.32 -96.41 -167.3
Operating Margin -1,750% -108.88% -173.95% -1,409.68% -1,015.56% -327.4% -185.24% -1,639.87%
Earnings before Tax (EBT) 1 -123.3 -42.6 -62.6 -88.8 -89.3 -94.09 -95.84 -166.9
Net income 1 -123.4 -42.6 -63.1 -88.8 -89.3 -94.09 -95.84 -166.9
Net margin -1,713.89% -108.12% -176.75% -1,432.26% -992.22% -316.52% -184.13% -1,636.68%
EPS 2 -5.080 -1.750 -1.200 -1.590 -1.480 -0.7990 -1.271 -1.461
Free Cash Flow 1 -149.7 -63.5 -48.7 -102.2 -60 -24 -170 -204
FCF margin -2,079.04% -161.17% -136.41% -1,648.39% -666.67% -80.74% -326.61% -2,000%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 13/02/20 26/02/21 15/02/22 15/02/23 15/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4
Net sales 1 11.4 18.8 15.3 0.9 0.9 1.8 2 2.5 0.8 2.6 3.3 1 4.7 0.6 0.45 1.5 0.55 0.6
EBITDA - - - - - - - - - - - - - - - - - -
EBIT 1 - - - - -22.1 - -14.6 -18.7 - - - -24.1 -20.8 -27.4 -29.23 -37.3 -30.59 -31.51
Operating Margin - - - - -2,455.56% - -730% -748% - - - -2,410% -442.55% -4,566.67% -6,494.64% -2,486.67% -5,562.14% -5,252.01%
Earnings before Tax (EBT) 1 -36.1 -25.4 -24.3 -32.7 -23.1 -55.9 -14.8 -18.1 -18.9 -26.6 -45.5 -23.6 -20.3 -26.1 -32.83 -34.4 -34.79 -35.81
Net income 1 -36.1 -25.5 -24.3 -32.7 -23.1 -55.9 -14.8 -18.1 -18.9 -26.6 -45.5 -23.6 -20.3 -26.1 -32.83 -34.4 -34.79 -35.81
Net margin -316.67% -135.64% -158.82% -3,633.33% -2,566.67% -3,105.56% -740% -724% -2,362.5% -1,023.08% -1,378.79% -2,360% -431.91% -4,350% -7,294.64% -2,293.33% -6,325.78% -5,968.68%
EPS 2 -1.490 -0.5700 -0.4400 -0.5900 -0.4200 -1.000 -0.2700 -0.3200 -0.3400 -0.4700 -0.8100 -0.4200 -0.2800 -0.2300 -0.2645 -0.3000 -0.3175 -0.3225
Dividend per Share - - - - - - - - - - - - - - - - - -
Announcement Date 20/08/20 19/08/21 15/02/22 28/04/22 19/08/22 19/08/22 03/11/22 15/02/23 27/04/23 18/08/23 18/08/23 27/10/23 15/02/24 30/04/24 - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 90.6 70 221 117 170 175 267 65
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -150 -63.5 -48.7 -102 -60 -24 -170 -204
ROE (net income / shareholders' equity) -50.2% -26.1% -29.8% - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 7.590 5.840 5.040 3.460 3.610 2.950 2.930 1.110
Cash Flow per Share - - - - - - - -
Capex 1 1.44 5.4 - 0.4 0.3 - 1 3
Capex / Sales 19.94% 13.71% - 6.45% 3.33% - 1.92% 29.41%
Announcement Date 13/02/20 26/02/21 15/02/22 15/02/23 15/02/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Medivir AB

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.1 SEK
Average target price
21.16 SEK
Spread / Average Target
+582.46%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MEDIVIR AB Stock Medivir AB
+3.51% 32.73M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.10% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.29% 113B
ARGENX SE Stock argenx SE
+19.13% 26.49B
BIONTECH SE Stock BioNTech SE
-23.25% 19.4B
GENMAB A/S Stock Genmab A/S
-19.03% 16.24B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.24% 15.4B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.15B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.01% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.59% 13.52B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MVIR B Stock
  4. Financials Medivir AB